AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company's research and manufacturing footprint by the end of 2026. This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs contributing to the growth of the US economy. AstraZeneca's expanding footprint in the US includes, among others: A state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusett.

AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States

CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary     9M 2024 % Change Q3 2024 % Change $m Actual CER1 $m Actual CER - Product Sales 37,576 16 19 12,947 18 20 - Alliance Revenue   1,498 49 50 559 48 50 - Collaboration Revenue 108 (66) (66) 59 (39) (40) Total Revenue   39,182 16 19 13,565 18 21 Reported EPS $3.57 11 21 $0.92 4 17 Core2 EPS $6.12 5 11 $2.08 20 27 Financial performance for 9M 2024 (Growth numbers at constant exchange rates) Total Revenue up 19% to $3.

AstraZeneca's 9M and Q3 2024 results

AstraZeneca PLC (LSE:AZN) raised its 2024 sales and profit outlook for the second time in under four months, following stronger-than-expected third-quarter results. The Anglo-Swedish drugs giant now projects that annual revenue and core earnings per share will increase by a high-teens percentage, up from a previous forecast of mid-teens growth, based on constant currency rates.

AstraZeneca upgrades outlook for the second time on four months

AstraZeneca PLC (LSE:AZN) has announced a $3.5 billion investment to expand its research and manufacturing operations in the United States by 2026, with $2 billion allocated to creating more than 1,000 high-skilled jobs. AZ said the expansion is the first step in its 'Ambition 2030' plan, through which it aims to reach $80 billion in total revenue by 2030.

AstraZeneca plans quick-fire $3.5bn US investment

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time in less than four months on Tuesday, helped by resilient demand for its cancer and rare diseases medicines, after third-quarter results beat estimates.

AstraZeneca lifts 2024 revenue and profit forecast after Q3 beat

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have submitted a new Biologics License Application (BLA) for accelerated approval in the U.S. for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NSCLC) who have received prior systemic therapies, including an EGFR-directed therapy. The companies.

Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Axsome Therapeutics

Novavax

Prothena

Theravance Biopharma

Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.

Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?

Shell PLC

Vodafone Group

A busy Tuesday will see AstraZeneca, Vodafone and Flutter all report, while UK unemployment figures and Shell's court ruling in the Netherlands will also be in focus.

AstraZeneca, Vodafone, Shell court ruling set the stage for busy Tuesday

NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.

ATTENTION AstraZeneca PLC Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights

Viking Therapeutics

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here's how Americans voted on abortion access.

Healthy Returns: Weight loss drug race heats up with pill data from Viking Therapeutics, AstraZeneca

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product.

ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product

At the start of September when its share price was at an all-time high and it was comfortably the UK's largest company, AstraZeneca PLC (LSE:AZN) management might have been expecting a routine third-quarter update. Two months on however and £50 billion has been wiped from its value with growing questions over its pipeline and operation in China.

AstraZeneca has explaining to do after £50 billion value hit

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that AstraZeneca and Amgen's TEZSPIRE® (tezepelumab) demonstrated a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo. WAYPOINT is a randomized, double-blind trial that evaluated the efficacy and safety of TEZSPIRE administe.

TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps

AstraZeneca PLC (LSE:AZN) and Amgen Inc (NASDAQ:AMGN, ETR:AMG) have unviled positive results from their phase III WAYPOINT study, which tested the effectiveness of Tezspire (tezepelumab) in treating chronic rhinosinusitis with nasal polyps. The research found the drug, currently used to treat severe asthma, significantly reduced the size of nasal polyps and decreased nasal congestion compared to a placebo.

AstraZeneca hails positive phase III data for repurposed asthma treatment

Astrazeneca (AZN) reachead $64.69 at the closing of the latest trading day, reflecting a +1.32% change compared to its last close.

Astrazeneca (AZN) Surpasses Market Returns: Some Facts Worth Knowing

NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.

ATTENTION AZN SHAREHOLDERS: Investors who lost money on AstraZeneca PLC are urged to contact Levi & Korsinsky about an ongoing investigation

AstraZeneca's price plunge following a fraud investigation in China could be just the time to buy the stock as the big picture looks positive. The company's numbers were strong in H1 2024 and its earnings release for Q3 2024 is expected to continue reflecting financial healthy. The combination of a positive outlook for 2024 and the latest price drop also makes the forward P/E attractive.

AstraZeneca: Contrarian Buy After The China Challenge (Rating Upgrade)

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Astrazeneca (AZN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.

Unveiling Astrazeneca (AZN) Q3 Outlook: Wall Street Estimates for Key Metrics

AstraZeneca PLC's (LSE:AZN) stock has suffered in recent days, losing 15% of its value as details emerged about ongoing investigations involving the company's operations in China. Shore Capital analysts have offered further insight into the factors impacting the Anglo-Swedish giant, noting that Chinese authorities are investigating several issues involving the drugmaker's current and former employees.

AstraZeneca's China challenges explained

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading and diverse pipeline in hematology at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition December 7-10, 2024. A total of 57 abstracts will feature 13 approved and potential new medicines from across AstraZeneca's portfolio and pipeline in hematology, including from Alexion, its rare disease group, with data in key settings including chro.

AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024

AstraZeneca's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.

Buy, Sell, or Hold AstraZeneca Stock? Key Tips Ahead of Q3 Earnings

Leon Wang, executive vice president in charge of China and the broader Asian region, is being detained while the Chinese government is probing AstraZeneca employees, the drugmaker says.

China Has Detained a Senior AstraZeneca Executive

AstraZeneca said on Wednesday that to its knowledge an ongoing investigation by Chinese authorities into the company's top executive, Leon Wang, is separate from a large health insurance fraud case also involving the company.

AstraZeneca: China's investigation into exec separate from medical insurance probe

AstraZeneca PLC (LSE:AZN) has committed to working with Chinese authorities after reports several executives were implicated in a fraud case wiped billions off its valuation on Tuesday.  Financial media firm Yicai reported dozens of AstraZeneca China senior executives were involved in the country's largest pharmaceutical insurance fraud case for years.

AstraZeneca commits to cooperting with China fraud probe after billions wiped from valuation

AstraZeneca (AZN) shares dropped Tuesday after a report that dozens of the company's senior executives in China potentially have been implicated in an insurance fraud case, according to a report from The Guardian citing a financial media firm in the country.

News for AstraZeneca Stock (AZN)